Nuclear medicine clinical practices for neoplasic disease diagnose and treatment are based on the incorporation of α , β and γ radiotracers and radiopharmaceuticals, which might be associated with potential damage. Thus, being necessary accurate dosimetry strategies. In vivo absorbed dose appears as an ideal solution. However, its implementation in clinics does not attain enough reliability. In...

68Ga faces a renaissance initiated by the development of new 68Ge/68Ga radionuclide generators, sophisticated 68Ga radiopharmaceuticals, preclinical research and state-of-the-art clincial diagnoses via positron emission tomography/computed tomography (PET/CT). A new type of 68Ge/68Ga generator became commercially available in the first years of the 21st century, with eluates based on hydrochlor...

INTRODUCTION The use of radionuclides in medical practice, either for diagnosis or for treatment, has grown steadily in recent years due to the introduction of new radiopharmaceuticals and equipment. Surveys of population doses derived from medical procedures have been conducted in several countries, but in Brazil this information has been scarce or non-existent. We thus decided to undertake a ...

Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the ⁶⁸Ga-radiopharmaceu...

The development of chelating agents for copper radionuclides in positron emission tomography radiopharmaceuticals has been a highly active and important area of study in recent years. The rapid evolution of chelators has resulted in highly specific copper chelators that can be readily conjugated to biomolecules and efficiently radiolabeled to form stable complexes in vivo. Chelators are not onl...

UNLABELLED We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS 1,024,1...

The training requirements for the supervision and administration of therapeutic procedures using radiopharmaceuticals are not defined uniformly in the Accreditation Council of Graduate Medical Education (ACGME) program requirements for different specialties. The training requirements of the Nuclear Regulatory Commission (NRC) are intended for the safe handling of radioisotopes, which is only a ...